ALXN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALXN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Alexion Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Mar. 2021 was $2.89. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2021 was $3.14.
Alexion Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2021 was $2.86. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2021 was $3.06.
Alexion Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2021 was $2.86. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2021 was 3.06.
During the past 12 months, Alexion Pharmaceuticals's average EPS without NRIGrowth Rate was -71.20% per year. During the past 3 years, the average EPS without NRI Growth Rate was 11.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 35.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was 14.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Alexion Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 82.50% per year. The lowest was -76.00% per year. And the median was -7.50% per year.
The historical data trend for Alexion Pharmaceuticals's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alexion Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | |||||||||||
EPS (Basic) | Get a 7-Day Free Trial | 1.78 | 1.98 | 0.35 | 10.77 | 2.74 |
Alexion Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | |
EPS (Basic) | Get a 7-Day Free Trial | 2.52 | -4.84 | 2.64 | 2.45 | 2.89 |
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Alexion Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2020 is calculated as
Basic EPS (A: Dec. 2020 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Basic Average) |
= | (603.4 | - | 0) | / | 220.100 | |
= | 2.74 |
Alexion Pharmaceuticals's Basic EPS for the quarter that ended in Mar. 2021 is calculated as
Basic EPS (Q: Mar. 2021 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Basic Average) |
= | (636 | - | 0) | / | 220.100 | |
= | 2.89 |
EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.14
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alexion Pharmaceuticals (NAS:ALXN) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Alexion Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.
Daniel Bazarko | officer: SVP, Controller, CAO | C/O ALEXION PHARMACEUTICALS, INC. 121 SEAPORT BOULEVARD BOSTON MA 02210 |
Tanisha Carino | officer: EVP & CCAO | C/O ALEXION PHARMACEUTICALS, INC., 121 SEAPORT BOULEVARD, BOSTON MA 02210 |
Anne-marie Law | officer: EVP, Chief Experience Officer | C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015 |
Brian Goff | officer: EVP & Chief Commercial Officer | C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510 |
John J Orloff | officer: EVP, Research & Development | C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015 |
Indrani Lall Franchini | officer: EVP, Chief Compliance Officer | C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510 |
John T Mollen | director | 176 SOUTH STREET HOPKINTON MA 01748 |
David R Brennan | director | C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807 |
Baker Bros. Advisors (gp) Llc | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
L.p. 667, | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Andreas Rummelt | director | C/O ALEXION PHARMACEUTICALS, INC. 352 KNOTTER DRIVE CHESHIRE CT 06410 |
Francois Nader | director | 550 HILLS DRIVE, BEDMINSTER NJ 07921 |
Baker Brothers Life Sciences Lp | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Deborah Dunsire | director | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Judith A Reinsdorf | director | C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974 |
From GuruFocus
By GuruFocus Research GuruFocus Editor • 05-18-2021
By Business Wire Business Wire • 07-15-2021
By GuruFocus Research GuruFocus Editor • 06-21-2021
By GuruFocus Research GuruFocus Editor • 07-20-2021
By GuruFocus Research GuruFocus Editor • 05-19-2021
By Business Wire Business Wire • 04-20-2021
By GuruFocus Research GuruFocus Editor • 05-18-2021
By Business Wire Business Wire • 06-07-2021
By GuruFocus Research GuruFocus Editor • 05-07-2021
By PRNewswire PRNewswire • 02-26-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.